Megestrol Acetate Oral Suspension
Longer Tamoxifen Use Helps Breast Cancer Survival »
"Dec. 5, 2012 -- Doubling the time that breast cancer patients take tamoxifen cuts the risk that the cancer will come back and further lowers the risk of dying of the disease, a new study shows.
The study is expected to change the way"...
Read the Longer Tamoxifen Use Helps Breast Cancer Survival article »
Megestrol Acetate Oral Suspension
SIDE EFFECTS
Clinical Adverse Events: Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. All patients listed had at least one post baseline visit during the 12 study weeks. These adverse events should be considered by the physician when prescribing megestrol acetate oral suspension.
ADVERSE EVENTS
% of Patients Reporting
| Trial 1 (N=236) |
Trial 2 (N=87) |
||||||
| Megestrol Acetate mg/day No.of Patients |
Placebo 0 N=34 |
100 N=68 |
400 N=69 |
800 N=65 |
Placebo 0 N=38 |
800 N=49 |
Open Label Trial 1200 N=176 |
| Diarrhea | 15 | 13 | 8 | 15 | 8 | 16 | 10 |
| Impotence | 13 | 14 | 6 | 14 | 0 | 14 | 17 |
| Rash | 19 | 19 | 4 | 12 | 3 | 12 | 16 |
| Flatulence | 19 | 10 | 1 | 19 | 3 | 10 | 16 |
| Hypertension | 10 | 10 | 0 | 18 | 0 | 10 | 14 |
| Asthenia | 13 | 12 | 3 | 16 | 8 | 14 | 15 |
| Insomnia | 10 | 13 | 4 | 16 | 0 | 10 | 11 |
| Nausea | 19 | 14 | 0 | 15 | 3 | 14 | 15 |
| Anemia | 16 | 13 | 3 | 15 | 0 | 10 | 10 |
| Fever | 13 | 16 | 4 | 15 | 3 | 12 | 11 |
| Libido Decreased | 13 | 14 | 0 | 15 | 0 | 12 | 11 |
| Dyspepsia | 10 | 10 | 3 | 13 | 5 | 14 | 12 |
| Hyperglycemia | 13 | 10 | 6 | 13 | 0 | 10 | 13 |
| Headache | 16 | 10 | 1 | 13 | 3 | 10 | 13 |
| Pain | 16 | 10 | 0 | 12 | 5 | 16 | 14 |
| Vomiting | 19 | 13 | 0 | 12 | 3 | 16 | 14 |
| Pneumonia | 16 | 12 | 0 | 12 | 3 | 10 | 11 |
| Urinary Frequency | 10 | 10 | 1 | 12 | 5 | 12 | 11 |
Adverse events which occurred in 1 to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system. Adverse events occurring less than 1% are not included. There were no significant differences between incidence of these events in patients treated with megestrol acetate and patients treated with placebo.
Body as a Whole - abdominal pain, chest pain, infection, moniliasis and sarcoma Cardiovascular System - cardiomyopathy and palpitation
Digestive System - constipation, dry mouth, hepatomegaly, increased salivation and oral moniliasis
Hemic and Lymphatic System - leukopenia
Metabolic and Nutritional - LDH increased, edema and peripheral edema
Nervous System - paresthesia, confusion, convulsion, depression, neuropathy, hypesthesia and abnormal thinking
Respiratory System - dyspnea, cough, pharyngitis and lung disorder
Skin and Appendages - alopecia, herpes, pruritus, vesiculobullous rash, sweating and skin disorder
Special Senses - amblyopia
Urogenital System - albuminuria, urinary incontinence, urinary tract infection and gynecomastia
Postmarketing - Postmarketing reports associated with megestrol acetate oral suspension included throm-boembolic phenomena including thrombophlebitis and pulmonary embolism and glucose intolerance (see WARNINGS and PRECAUTIONS sections).
Read the Megestrol Acetate Oral Suspension (megestrol acetate oral suspension) Side Effects Center for a complete guide to possible side effects »
DRUG INTERACTIONS
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. The effects of zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
Last reviewed on RxList: 6/3/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Megestrol Acetate Oral Suspension Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Breast Cancer
Find support and advances in treatment.
Updated & New
